Orgenesis (ORGS) Competitors $0.15 -0.85 (-85.00%) As of 10/17/2025 10:24 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. MTEX, THAR, NXTC, GOVX, CMMB, EDSA, FBLG, BLRX, LPCN, and LEXXShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Mannatech (MTEX), Tharimmune (THAR), NextCure (NXTC), GeoVax Labs (GOVX), Chemomab Therapeutics (CMMB), Edesa Biotech (EDSA), FibroBiologics (FBLG), BioLineRx (BLRX), Lipocine (LPCN), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors Mannatech Tharimmune NextCure GeoVax Labs Chemomab Therapeutics Edesa Biotech FibroBiologics BioLineRx Lipocine Lexaria Bioscience Orgenesis (NASDAQ:ORGS) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Which has more risk & volatility, ORGS or MTEX? Orgenesis has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Does the media favor ORGS or MTEX? In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score. Company Overall Sentiment Orgenesis Neutral Mannatech Neutral Is ORGS or MTEX more profitable? Mannatech has a net margin of -3.46% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Mannatech's return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Mannatech -3.46%-48.60%-10.70% Do analysts recommend ORGS or MTEX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals and insiders believe in ORGS or MTEX? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, ORGS or MTEX? Mannatech has higher revenue and earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K1.09-$55.36MN/AN/AMannatech$117.87M0.15$2.49M-$2.04-4.63 SummaryMannatech beats Orgenesis on 6 of the 10 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$720K$1.03B$6.14B$10.55BDividend YieldN/A4.84%5.72%4.84%P/E RatioN/A1.2929.4727.34Price / Sales1.09170.96567.66227.59Price / CashN/A17.6325.8230.35Price / Book-0.028.0312.436.69Net Income-$55.36M-$7.47M$3.32B$276.46M7 Day Performance-85.00%-0.09%1.84%-0.08%1 Month PerformanceN/A29.45%8.84%3.93%1 Year Performance-90.74%-12.99%63.12%33.89% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesis1.5143 of 5 stars$0.15-85.0%N/A-92.9%$720K$662K0.00150Gap UpMTEXMannatech0.2912 of 5 stars$9.74-3.2%N/A+17.4%$18.51M$117.87M-4.77250Gap UpHigh Trading VolumeTHARTharimmune1.7774 of 5 stars$3.12+6.8%$17.00+444.9%+44.3%$18.41MN/A-0.512Analyst DowngradeShort Interest ↑Gap UpNXTCNextCure4.5556 of 5 stars$6.72+5.8%$25.50+279.5%-34.2%$18.01MN/A-0.2690Short Interest ↓Gap DownGOVXGeoVax Labs2.3308 of 5 stars$0.60+8.7%$8.50+1,306.6%-71.8%$17.95M$3.95M-0.3010CMMBChemomab Therapeutics2.4289 of 5 stars$3.45+2.7%$26.50+668.1%-45.9%$17.84MN/A-1.4620High Trading VolumeEDSAEdesa Biotech2.0088 of 5 stars$2.51-1.2%$5.00+99.2%-40.4%$17.67MN/A-1.9020FBLGFibroBiologics2.5121 of 5 stars$0.42-4.2%$12.67+2,916.6%-87.9%$17.59MN/A-1.1710High Trading VolumeBLRXBioLineRx1.7259 of 5 stars$4.02+4.4%$26.00+546.8%-80.1%$17.49M$28.94M-0.4640LPCNLipocine1.8131 of 5 stars$3.21+3.2%$8.00+149.2%-44.2%$17.40M$11.20M-3.6910Gap DownLEXXLexaria Bioscience2.3891 of 5 stars$0.87-3.2%$4.00+357.7%-65.8%$17.10M$460K-1.307Short Interest ↑Gap Up Related Companies and Tools Related Companies Mannatech Alternatives Tharimmune Alternatives NextCure Alternatives GeoVax Labs Alternatives Chemomab Therapeutics Alternatives Edesa Biotech Alternatives FibroBiologics Alternatives BioLineRx Alternatives Lipocine Alternatives Lexaria Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
